Publicaciones en colaboración con investigadores/as de Mayo Clinic (133)

2024

  1. A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function

    European Journal of Heart Failure, Vol. 26, Núm. 4, pp. 707-729

  2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  3. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

    Blood Advances

  4. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  5. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  6. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome

    JHEP Reports, Vol. 6, Núm. 7

  7. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  8. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

    Nature Communications

  2. Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma

    Frontiers in Endocrinology, Vol. 13

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Disease Monitoring In Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia

  5. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

    New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014

  6. Mechanical Thrombectomy Global Access for Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study

    Circulation, Vol. 147, Núm. 16, pp. 1208-1220

  7. Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome

    Annals of surgery, Vol. 278, Núm. 5, pp. e1041-e1047

  8. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome

    Hepatology, Vol. 77, Núm. 5, pp. 1527-1539

  9. Pathophysiology of migraine aura

    Handbook of Clinical Neurology (Elsevier B.V.), pp. 71-83

  10. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

    Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373

  11. Zonation of lipid droplet formation and metabolism in alcohol-associated liver disease

    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH

2022

  1. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293